Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 4358Neoplasms 3060Prostatic Neoplasms 1904Colorectal Neoplasms 1739Lung Neoplasms 1557Carcinoma, Non-Small-Cell Lung 1270Pancreatic Neoplasms 981Leukemia, Myeloid, Acute 952Multiple Myeloma 951Lymphoma 912Head and Neck Neoplasms 894Leukemia 852Precursor Cell Lymphoblastic Leukemia-Lymphoma 833Neoplasm Metastasis 794Colonic Neoplasms 786Carcinoma, Hepatocellular 762Ovarian Neoplasms 758Melanoma 752Stomach Neoplasms 743Rectal Neoplasms 701Brain Neoplasms 699Lymphoma, Non-Hodgkin 663Leukemia, Lymphocytic, Chronic, B-Cell 618Uterine Cervical Neoplasms 608Lymphoma, Follicular 559Glioblastoma 542Recurrence 541Hodgkin Disease 532Esophageal Neoplasms 527Myelodysplastic Syndromes 508

Interventions

cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × OTHER × Metastatic Hormone Refractory Prostate Cancer × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

NCT00636090 2013-12-04

Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001

Duke University

Completed
35 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡